You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Type 2 Inflammation

Understanding the Pathophysiology of Pediatric Type 2 Inflammatory Diseases

Prof. Oscar Palomares discusses the underlying pathophysiology of type 2 inflammation in pediatric patients with AD, asthma, or EoE.

Oscar Palomares
PhD
Oscar Palomares

Learning objectives

  • Evaluate the key and central role of IL-4 and IL-13 in local and systemic effects of disease pathology, and the role of IL-4 in driving type 2 amplification and chronicity of disease progression
  • Understand the importance of understanding potential disease trajectories in pediatric patients, and the onset and persistence of type 2 inflammation

Description

Join global expert Oscar Palomares, PhD, as he discusses the shared and distinct elements of underlying type 2 pathophysiology in atopic dermatitis (AD), asthma, and eosinophilic esophagitis (EoE).

Tags
th2 polarizationsymptomspediatric
MAT-GLB-2302311 v2.0 06/2023

About this expert

Allergy/Immunology

Oscar Palomares

PhD

Complutense University of Madrid

See author’s profile
Oscar Palomares

Related resources

Type 2 Inflammation as the Common Thread in Multiple Diseases
Type 2 Inflammation
videoanimation

Type 2 Inflammation as the Common Thread in Multiple Diseases

Cumulative Exposure to Corticosteroids in Type 2 Inflammatory Diseases
Type 2 Inflammation
expert video

Cumulative Exposure to Corticosteroids in Type 2 Inflammatory Diseases

EAACI 2023 | Pediatric Type 2 Inflammatory Disease Progression
Type 2 Inflammation
expert video

EAACI 2023 | Pediatric Type 2 Inflammatory Disease Progression

Type 2 Inflammatory Disease Trajectories: Unraveling Patterns of Disease Development and Burden in Pediatric Patients
Type 2 Inflammation
expert video

Type 2 Inflammatory Disease Trajectories: Unraveling Patterns of Disease Development and Burden in Pediatric Patients

Understanding the Pathophysiology of Pediatric Type 2 Inflammatory Diseases
Type 2 Inflammation
expert video

Understanding the Pathophysiology of Pediatric Type 2 Inflammatory Diseases

Genetics of Type 2 Inflammation
Type 2 Inflammation
expert video

Genetics of Type 2 Inflammation

Impact of Type 2 Inflammation on Pediatric Atopic Dermatitis, Asthma and Eosinophilic Esophagitis
Type 2 Inflammation
expert video

Impact of Type 2 Inflammation on Pediatric Atopic Dermatitis, Asthma and Eosinophilic Esophagitis

AAAAI 2023 | Pediatric Type 2 Inflammatory Disease Progression
Type 2 Inflammation
expert video

AAAAI 2023 | Pediatric Type 2 Inflammatory Disease Progression

AAAAI 2023 | Defining Type 2 Inflammation
Type 2 Inflammation
expert video

AAAAI 2023 | Defining Type 2 Inflammation

AAAAI 2023 | Impact of Barrier Disruption and Type 2 Inflammation in Pediatric Patients With AD
Type 2 Inflammation
expert video

AAAAI 2023 | Impact of Barrier Disruption and Type 2 Inflammation in Pediatric Patients With AD

AAAAI 2023 | How Type 2 Inflammation Can Contribute to the Progression of Asthma in Children
Type 2 Inflammation
expert video

AAAAI 2023 | How Type 2 Inflammation Can Contribute to the Progression of Asthma in Children

AAAAI 2023 | The Role of Type 2 Inflammation in EoE Disease Progression Throughout the Lifespan
Type 2 Inflammation
expert video

AAAAI 2023 | The Role of Type 2 Inflammation in EoE Disease Progression Throughout the Lifespan

Atopic Dermatitis and the Type 2 Inflammatory Disease Spectrum
Type 2 Inflammation
expert video

Atopic Dermatitis and the Type 2 Inflammatory Disease Spectrum

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD
Type 2 Inflammation
expert video

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD

Pruritic Dermatoses with a Type 2 Inflammation Component
Type 2 Inflammation
expert video

Pruritic Dermatoses with a Type 2 Inflammation Component

Connecting the Dots from Type 2 Inflammation to Patient Perspectives
Type 2 Inflammation
expert video

Connecting the Dots from Type 2 Inflammation to Patient Perspectives

Role of Type 2 Inflammation Across Different Chronic Diseases
Type 2 Inflammation
expert video

Role of Type 2 Inflammation Across Different Chronic Diseases

Trajectories of Type 2 Inflammation in Pediatric Patients
Type 2 Inflammation
expert video

Trajectories of Type 2 Inflammation in Pediatric Patients

Multidisciplinary Partnership for Type 2 Inflammatory Diseases
Type 2 Inflammation
expert video

Multidisciplinary Partnership for Type 2 Inflammatory Diseases

Evolving Topics in Type 2 Inflammation
Type 2 Inflammation
expert video

Evolving Topics in Type 2 Inflammation

Type 2 Inflammation Acts on a Range of Skin Barrier Components to Drive Atopic Dermatitis Interview
Type 2 Inflammation
expert video

Type 2 Inflammation Acts on a Range of Skin Barrier Components to Drive Atopic Dermatitis Interview

The Role of Type 2 Inflammation in the Pathophysiology of Atopic Dermatitis
Type 2 Inflammation
expert video

The Role of Type 2 Inflammation in the Pathophysiology of Atopic Dermatitis

The Role of IL-4 in Type 2 Inflammation
Type 2 Inflammation
expert video

The Role of IL-4 in Type 2 Inflammation

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?
Type 2 Inflammation
expert video

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?
Type 2 Inflammation
expert video

Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?

Impact of Advanced Systemic Therapies on Disease Control in AD
Type 2 Inflammation
expert video

Impact of Advanced Systemic Therapies on Disease Control in AD

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone
Type 2 Inflammation
expert video

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

What proportion of patients can achieve control in CRSwNP?
Type 2 Inflammation
expert video

What proportion of patients can achieve control in CRSwNP?

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?
Type 2 Inflammation
expert video

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?
Type 2 Inflammation
expert video

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?
Type 2 Inflammation
expert video

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

When is the right time to consider a biologic in patients with CRSwNP?
Type 2 Inflammation
expert video

When is the right time to consider a biologic in patients with CRSwNP?

How often do you suggest to assess sense of smell?
Type 2 Inflammation
expert video

How often do you suggest to assess sense of smell?

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?
Type 2 Inflammation
expert video

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?

Explore the Global Burden of Pediatric AD (PEDISTAD)
Type 2 Inflammation
interactivity

Explore the Global Burden of Pediatric AD (PEDISTAD)

ADVENT Forum 2022 | Exploring Features in Type 2 Inflammation
Type 2 Inflammation
expert video

ADVENT Forum 2022 | Exploring Features in Type 2 Inflammation

ADVENT Forum 2022 | Delving Into the Latest Pediatric Data for Systemic Agents in AD and Asthma
Type 2 Inflammation
expert video

ADVENT Forum 2022 | Delving Into the Latest Pediatric Data for Systemic Agents in AD and Asthma

ADVENT Forum 2022 | Multidisciplinary Management of Patients with Type 2 Inflammatory Diseases
Type 2 Inflammation
expert video

ADVENT Forum 2022 | Multidisciplinary Management of Patients with Type 2 Inflammatory Diseases

ADVENT Forum 2022 | Therapeutic Mechanisms Targeting Type 2 Pathophysiology
Type 2 Inflammation
expert video

ADVENT Forum 2022 | Therapeutic Mechanisms Targeting Type 2 Pathophysiology

ADVENT Forum 2022 | Type 2 Inflammation Underlies the Pathophysiology of Multiple Diseases
Type 2 Inflammation
expert video

ADVENT Forum 2022 | Type 2 Inflammation Underlies the Pathophysiology of Multiple Diseases

Managing Type 2 Inflammatory Diseases: Multidisciplinary Frame of Mind
Type 2 Inflammation
expert video

Managing Type 2 Inflammatory Diseases: Multidisciplinary Frame of Mind

Key Type 2 Cytokines Impact the Skin Microbiome in Atopic Dermatitis
Type 2 Inflammation
expert video

Key Type 2 Cytokines Impact the Skin Microbiome in Atopic Dermatitis

ADVENT On Air | Exploring PN as a Distinct and Unique Disease
Type 2 Inflammation
audio

ADVENT On Air | Exploring PN as a Distinct and Unique Disease

ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet
Type 2 Inflammation
audio

ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?
Type 2 Inflammation
audio

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?
Type 2 Inflammation
expert video

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

Can early intervention modify the course of AD?
Type 2 Inflammation
expert video

Can early intervention modify the course of AD?

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi | Regeneron Logo

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region